RxDoctor Payments Data

Paul Algeo

Physician Assistant · Seattle, WANPI 1891039418

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Gilead accounts for 61.1% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $4,158 and has fallen 97.6% since, to $100 in 2025. Among physician assistant clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,808in general payments, 2019–2025

Across 155 payments — averaging $43.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$4K
  • Viiv Healthcare Company$976
  • Johnson & Johnson$467
  • Pfizer$223
  • EMD Serono, Inc.$200
  • Merck$116
  • plus $668 from 13 others

What the payments were for

  • Consulting fees$1,57023%
  • Travel & lodging$1,62924%
  • Food & beverage$3,43050%
  • Education$1783%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,808 in reported general payments places this provider in the 95th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala16$60,613
DescovyEmtricitabine/Tenofov Alafenam12$31,698
DovatoDolutegravir Sodium/Lamivudine11$31,078
Etravirine11$12,925
Combivent RespimatIpratropium/Albuterol Sulfate11$5,331
VascepaIcosapent Ethyl11$3,682
Nevirapine ErNevirapine11$1,896
Ventolin HfaAlbuterol Sulfate11$626
Rosuvastatin Calcium54$481
Omeprazole21$220
Tamsulosin Hcl20$198
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide13$183
Finasteride17$134
Aripiprazole11$129
Atorvastatin Calcium15$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$4,159$92,31228 claims
Viiv Healthcare CompanyDovato$976$31,07811 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$12$9912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →